Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037

被引：5

作者：

Gege, Christian ^{[1
]}

Kleymann, Gerald ^{[1
]}

机构：

[1] Innovat Mol GmbH, Dachauer Str 65, D-80335 Munich, Germany

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2022年 / 32卷 / 09期

关键词：

Amenamevir; antiviral; helicase-primase; herpes simplex virus; HN0037; HSV-1; HSV-2; IM-250; pritelivir; PRITELIVIR;

D O I：

10.1080/13543776.2022.2113873

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest for me-too approaches. We describe the opportunities and limitations of the helicase-primase inhibitor patent portfolio from Phaeno Therapeutics and propose the structure of their drug candidate HN0037, which has been in-licensed from Medshine Discovery.

引用

页码：933 / 937

页数：5

共 34 条

[11] Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2
Cannon, Luke
Tholouli, Eleni
Ward, Chris
Farooq, Hamzah
Kingston, Margaret
[J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2021, 32 (10) : 978 - 980
[12] Lead Development of Thiazolylsulfonamides with Carbonic Anhydrase Inhibitory Action
Carta, Fabrizio
Birkmann, Alexander
Pfaff, Tamara
Buschmann, Helmut
Schwab, Wilfried
Zimmermann, Holger
Maresca, Alfonso
Supuran, Claudiu T.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (07) : 3154 - 3164
[13] UROTHELIAL HYPERPLASIA INDUCED BY CARBONIC-ANHYDRASE INHIBITORS (CAIS) IN ANIMALS AND ITS RELATIONSHIP TO URINARY NA AND PH
DURANDCAVAGNA, G
OWEN, RA
GORDON, LR
PETER, CP
BOUSSIQUETLEROUX, C
[J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1992, 18 (01): : 137 - 143
[14] A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections
Gege, Christian
Bravo, Fernando J.
Uhlig, Nadja
Hagmaier, Timo
Schmachtenberg, Rosanne
Elis, Julia
Burger-Kentischer, Anke
Finkelmeier, Doris
Hamprecht, Klaus
Grunwald, Thomas
Bernstein, David, I
Kleymann, Gerald
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (598)
[15] Blood-brain barrier permeability considerations for CNS-targeted compound library design
Hitchcock, Stephen A.
[J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (03) : 318 - 323
[16] Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer's Disease (AD); Underwhelming Evidence against
Itzhaki, Ruth F.
[J]. VACCINES, 2021, 9 (06)
[17] Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of "Secondary'' Pharmaceutical Patents
Kapczynski, Amy
Park, Chan
Sampat, Bhaven
[J]. PLOS ONE, 2012, 7 (12):
[18] Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study
Kawashima, Makoto
Nemoto, Osamu
Honda, Mariko
Watanabe, Daisuke
Nakayama, Juichiro
Imafuku, Shinichi
Kato, Toshiyuki
Katsuramaki, Tsuneo
[J]. JOURNAL OF DERMATOLOGY, 2017, 44 (11) : 1219 - 1227
[19] New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Kleymann, G
Fischer, R
Betz, UAK
Hendrix, M
Bender, W
Schneider, U
Handke, G
Eckenberg, P
Hewlett, G
Pevzner, V
Baumeister, J
Weber, O
Henninger, K
Keldenich, J
Jensen, A
Kolb, J
Bach, U
Popp, A
Mäben, J
Frappa, I
Haebich, D
Lockhoff, O
Rübsamen-Waigmann, H
[J]. NATURE MEDICINE, 2002, 8 (04) : 392 - 398
[20] Knipe D.M., 2013, FIELDS VIROLOGY, Vsixth

← 1 2 3 4 →